Valuation: COSCIENS Biopharma

Market Cap 7.89M 6.91M 6.36M 5.9M 11.2M 749M 11.38M 76.31M 29.68M 370M 29.63M 28.98M 1.28B P/E 2024
-0.45x
P/E 2025 -0.63x
Enterprise Value 2.73M 2.39M 2.2M 2.04M 3.88M 259M 3.94M 26.43M 10.28M 128M 10.26M 10.04M 443M EV / Sales 2024
-0.97x
EV / Sales 2025 0.19x
Free-Float
33.15%
Yield 2024 *
-
Yield 2025 -
1 day-4.18%
1 week+8.54%
Current month+8.54%
1 month+30.73%
3 months-11.64%
6 months+16.83%
Current year+23.83%
1 week 9.18
Extreme 9.18
11.1
1 month 7.71
Extreme 7.71
11.1
Current year 3.3
Extreme 3.3
13.2
1 year 3.3
Extreme 3.3
18
3 years 3.3
Extreme 3.3
50.76
5 years 3.3
Extreme 3.3
372
10 years 3.3
Extreme 3.3
2,228.99
Date Insider Type Main position Quantity % Market Cap.
03-05
Goodwood, Inc.
MarcheCompany 241,570 7.5883%
25-10-22Other

Director

0 0%
25-10-15Other

Chief Executive Officer

0 0%
Change 5-day change 1-year change 3-year change Capi.($)
-4.18%+8.54%-25.96%-75.78% 8.22M
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.25%+1.70%+419.39%+621.71% 40.39B
+1.10%+7.77%+28.18%-3.96% 34.38B
-0.16%+8.42%+28.20%+63.00% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
-0.35%+0.09% - - 16.64B
-3.33%+3.15%+71.30%+131.94% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.79%+8.88%+106.63%+106.63% 13.75B
Average -0.23%+6.49%+72.24%+100.92% 24.6B
Weighted average by Cap. +0.09%+5.08%+95.81%+141.26%

Financials

2024 2025
Net sales 9.59M 8.39M 7.73M 7.17M 13.6M 910M 13.82M 92.71M 36.05M 449M 35.99M 35.21M 1.55B 7.5M 6.56M 6.05M 5.6M 10.64M 712M 10.81M 72.51M 28.2M 351M 28.15M 27.54M 1.21B
Net income -15.31M -13.4M -12.35M -11.44M -21.72M -1.45B -22.07M -148M -57.57M -717M -57.47M -56.23M -2.48B -10.36M -9.06M -8.35M -7.74M -14.7M -983M -14.94M -100M -38.95M -485M -38.89M -38.04M -1.68B
Net Debt -14.08M -12.32M -11.36M -10.53M -19.98M -1.34B -20.31M -136M -52.96M -660M -52.87M -51.73M -2.28B -5.16M -4.51M -4.16M -3.86M -7.32M -490M -7.44M -49.88M -19.4M -242M -19.36M -18.95M -835M
Logo COSCIENS Biopharma
COSCIENS Biopharma Inc. is a Canada-based life science company. The Company is developing and commercializing a diversified portfolio of products for the cosmeceutical, nutraceutical and pharmaceutical markets. The Company’s patented technologies include the Pressurized Gas eXpanded (PGX) technology, which is a technology that generates high-value yields of active ingredients from natural-based resources for use in novel cosmeceutical, nutraceutical and pharmaceutical products. The Company's two products, oat beta glucan and avenanthramides, are found in household-name cosmetic and personal care brands. These products are manufactured from the Company’s proprietary oat extraction manufacturing technology and are known for their well-documented health benefits. Its lead product, macimorelin (Macrilen; Ghryvelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
Employees
28
Date Price Change Volume
26-07-07 $10.55 -4.18% 100
26-07-06 $11.01 +0.27% 185
26-07-03 $10.98 +4.87% 275
26-07-02 $10.47 +7.72% 817
26-06-30 $9.720 +8.00% 1,653

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSCI Stock